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Abstract
With more advanced and more aggressive chemotherapy cancer treatment leading
to higher survival rates, complications with quality of life are becoming more prominent.
Of these complications, delayed cognitive processing, commonly known as “chemo
brain,” is becoming a topic of interest. Cognitive changes are some of the most common
as well as most challenging complications associated with central nervous system (CNS)
directed treatment, such as intrathecal chemotherapy, for acute lymphoblastic leukemia
(ALL) and brain tumors. The term “chemo brain” is often used to describe self-reported
or observed cognitive processing delays in patients who receive chemotherapy as a form
of cancer treatment (Raffa, 2009). Although these cognitive delays have the potential to
be serious side effects, little education is given to the patients and families regarding
these possibilities prior to the initiation of cancer treatment. The purpose of this paper is
three fold: 1) to define and discuss the etiology of “chemo brain,” 2) discuss the best
assessment and evaluation of severity of “chemo brain,” and 3) to explore pediatric
oncology nurses reports of practice implications for teaching and supporting pediatric
patients and their families experiencing “chemo brain.” A theoretical framework that will
guide the research is Erikson’s Theory of Psychosocial Development with a focus on the
school age stage of industry versus inferiority. With the possible gap in knowledge and
skill that may be present in these children who have undergone chemotherapy, there is a
significantly higher chance of them developing a sense of inferiority rather than the
preferred sense of industry. Convenience and snowball sampling will be used to locate
pediatric oncology registered nurses to complete the research instrument. This pilot study
has a qualitative/descriptive design with a goal of 30 subjects. Research data will be
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collected through a short survey created by the primary investigator that has construct
and content validity from two advanced practice pediatric oncology nurses.
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Introduction
With more advanced and more aggressive chemotherapy cancer treatment leading
to higher survival rates, complications with quality of life are becoming more prominent,
especially delayed cognitive processing, commonly known as “chemo brain.” At
diagnosis and throughout treatment, patients and families are routinely educated about the
plan of care, but according to oncology nurses’ reports, too often details regarding the
possibility of cognitive declines or deficits are left out.
Background
Cognitive changes are some of the most common as well as challenging
complications associated with central nervous system (CNS) directed treatment, such as
intrathecal chemotherapy, for acute lymphoblastic leukemia (ALL) and brain tumors. The
estimated incidence of patients who experience deficits in cognitive processing related to
their CNS directed treatment is approximately 20% to 40% for children with ALL and
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40% to 100% for children with brain tumors (Moore et al., 2013). The term “chemo
brain” is often used to describe self-reported or observed cognitive processing delays in
patients who receive chemotherapy as a form of cancer treatment (Raffa, 2009). The
clinical manifestations of “chemo brain” can “affect multitasking, create stress, and
weaken performance when patients are challenged by high-level cognitive demands”
(Staat & Segatore, 2005).
Purpose
The purpose of this paper is three fold: 1) to define and discuss the etiology of
“chemo brain,” 2) discuss the best assessment and evaluation of severity of “chemo
brain,” and 3) to explore pediatric oncology nurses reports of practice implications for
teaching and supporting pediatric patients and their families experiencing “chemo brain”
(CB).
Literature Review
Introduction
“Chemo Brain” (CB) is a term used to describe the general cognitive deficit that
results from cancer chemotherapy treatment. According the Evens & Eschiti (2009), CB
can be simply described as “dysfunction, weakening, or impairment” of the memory in
patients who have undergone chemotherapy treatment for cancer. Raffa et al. (2006)
suggested that these impairments can be self-reported or observed. A more specific
definition of CB stated that it presents as “weakened cognitive abilities, speed of
information processing or reaction time, and organizational skills” along with the
negative impact on “language ability, memory, concentration, and attention” (Staat &
Segatore, 2005). Many of these core symptoms have been termed “executive functions,”
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mainly including the “ability to allocate attentional resources and to plan and organize
behavior” (Mulhern & Palmer, 2003). Although theses deficits may seem to cause
deteriorating effects, it is suggested that “young children aren’t actually dementing, but
rather are not acquiring new information and skills at an appropriate age” (Duffner, 2009)
According to Staat & Segatore (2005), the patient’s quality of life may be
significantly affected because of the severity of the CB symptoms. Cognitive deficits may
be subtle enough so only the patient and close relatives notice, but they also may be
severe enough to cause others to notice – which is noted to be most difficult for the
patient as well as their family and close friends.
Moore et al. (2013) and Evens & Eschiti (2009) both presented the statistic that
as many as 40% of pediatric acute lymphoblastic leukemia (ALL) patients who are
treated with chemotherapy alone will report CB. Overall, studies have shown that
cognitive difficulties affect 25%-35% of all patients that undergo systemic chemotherapy
(Evens & Eschiti, 2009).
Deficits of CB often appear over time rather than right away. In fact, myelination
changes in the central nervous system (CNS) from a chemotherapy drug, 5-fluorouracil
can be delayed for several months and may become progressive (Evens & Eschiti, 2009).
By the late 1990’s, reports began to suggest that children who were treated for ALL
without cranial radiation therapy but with chemotherapy developed progressive cognitive
declines 3-4 years following the completion of their chemotherapy (Duffner, 2009). More
detrimental, it has been suggested that in a small minority of patients, CB is still
perceptible 10 years after the completion of treatment (Staat & Segatore, 2005).
Etiology of “Chemo Brain”
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The deficits of CB are believed to occur because of alterations in the blood-brain
barrier (BBB), vascular injury, and myelination changes. With this BBB impairment,
toxic agents are allowed access to the brain more readily and in normal circumstances
where entry would not usually happen (Evens & Eschiti, 2009). In addition to these
abnormalities, Mulhern & Palmer (2003) suggested that the late effects might also
include diffuse and multifocal white matter abnormalities, microvascular occlusion, and
calcifications. While Raffa (2009) stated that mainly white matter abnormalities were
related to chemotherapy treatment, Evens & Eschiti (2009) discussed how researchers
have also shown a decrease in the brain’s grey matter along with the demyelination of
white matter fibers following chemotherapy treatment. In neuroimaging studies discussed
by Raffa (2009), changes were evident at about two months then appeared to plateau at
about six months and persisted for the duration of the study (which was about one year).
Staat and Segatore (2005) discussed three possible mechanisms that cause CB:
direct neurotoxicity, inflammatory mechanisms, or a vascular mechanism. The theory of
direct neurotoxicity implies that chemo agents cause direct toxicity to the brain,
producing demyelination. The theory of an inflammatory response has to do with chemo
agents destroying healthy cells in addition to cancer cells. This destruction of healthy
cells produces a physiologic stress and the brain interprets the inflammatory response and
the increase release of cytokines as stress, which may result in a decreased ability to
learn, memory difficulties, and poor concentration (Evens & Eschiti, 2009). The last
theory involves a vascular mechanism where injury obstructs the microvasculature of the
brain, causing ischemia or infarction of dependent brain tissue leading to the deficits of
CB (Staat & Segatore, 2005).
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Because cancer treatment is often multimodal, it is important to understand that
both chemotherapy and radiation may be used. If this is the case, it makes it very difficult
to separate the adverse effects (Raffa et al., 2006). According to Evens & Eschiti (2009),
Cyclophosphamide and 5-fluorouracil are two of the most commonly used chemo drugs
that can readily cross the BBB. Because of this, they are thought to significantly
contribute to CB. Although chemo drugs such as methotrexate (MTX) and vincristine are
not believed to penetrate the BBB, they are believed to play a role in altering its
permeability, which allows the drugs to gain entry to the brain, also contributing to CB.
According to Staat & Segatore (2005), cyclophosphamide, MTX, and fluorouracil in high
doses are known to have the strongest association with the development of CB. As
expected, more cognitive impairments were noted in patients who were given high doses
of chemo compared to a standard dose, and more cognitive impairment was seen in
patients given a standard dose of chemo than in control groups (Raffa et al., 2006). High
dose chemotherapy, especially with MTX, has been associated with the previously
discussed white matter injury (Mulhern & Palmer, 2003).
There are many risk factors and contributing factors relating to CB. Both Duffner
(2009) and Mulhern & Palmer (2003) discussed the finding that early age at diagnosis
and chemotherapy treatment has consistently been identified as a major risk factor for
developing CB. Mulhern & Palmer (2003) also discussed how being of female gender
confers a greater risk for developing CB. They also stated that the factors of early age at
diagnosis and start of chemo treatment along with low socioeconomic status were
associated with more severe CB in females, but did not reliably correlate in males. It has
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also been suggested that people who carry the APOE e4 gene (a gene associated with
Alzheimer’s) may be more susceptible to CB (Evens & Eschiti, 2009).

Assessment of Severity
Deficits of CB may me subtle, so they may only be noticeable to the patient and
family and not to the health care team. Evens & Eschiti (2009) provided the statistic that
only 38% of nurses assessed patients for CB. While longitudinal evaluation of cognitive
functioning for childhood cancer survivors is not yet considered standard of care, many
pediatric oncology programs emphasize cognitive assessment for high-risk patients
(Ullrich & Embry, 2012).
Because there may be different contributing factors to the cognitive decline, there
are differential diagnoses that must be ruled out in order to conclude that the deficits are
caused by the chemotherapy (Evens & Eschiti, 2009). According to Staat & Segatore
(2005), observational assessment is the most appropriate method to screen for CB.
The neurocognitive assessments are essential in facilitating access to the
necessary special education services and in tracking the child’s development over time.
Ullrich & Embry (2012) suggested that a comprehensive neurocognitive assessment
should focus on global intellectual functioning and academic achievement along with
other specific high-risk areas of deficit. They also discussed the recommendation that
high-risk survivors should be evaluated when they transition into a long-term follow-up
program. This should be done both to detect subtle impacts on overall functioning and to
serve as a baseline for future assessments since it is known that CB late effects can
progress over time. This reevaluation should look at factors such as academic
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performance, any acute changes or new difficulties, and the individual child’s specific
risk factors.
Ullrich & Embry (2012) also provided a table providing commonly used
assessment tools for assessing specific neurocognitive domains in children. To assess
global cognitive functioning (IQ), the WISC-IV is often used. The CPT-II or Trail
Making Test Part A are often used to assess attention. The CMS may be used to assess
memory. Processing speed may be assessed by the WISC-IV Coding/Symbol Search.
Executive functioning may be assessed by a few tests, including the BRIEF or the Trail
Making Test Part B. Finally, academic achievement may be assessed by the WIAT-III or
WJ-III assessment tools.
Practice Implications
According to Mulhern & Palmer (2003), interventions can be divided into
two approaches: those that aim to avoid or reduce the neurotoxicity of the CNS
therapy, and those that aim to minimize or rehabilitate deficits that are not
preventable. First, in order to determine potential interventions, the cognitive
deficits must be distinguished from brain metastases and other medical conditions
(Evens & Eschiti, 2009). The earlier the deficits are recognized and attributed to
chemotherapy treatment, the earlier potential treatments can begin.
One of the first implications of practice is education. Nurses play a significant
role in educating patients and families about the diagnosis, treatments, and
potential side effects. According to Staat & Segatore (2005), there is a huge debate
about whether or not the risk of CB should be disclosed during the consent process.
On one hand, when a treatment regimen has a known central neurotoxicity, it is
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required to provide informed consent. On the other hand, there is limited
knowledge regarding CB, and the incidence of CB must be confirmed before
including it in routine discussion and as part of the informed consent process.
Patients and families who have experienced CB first hand emphasized the desire for
full disclosure or risks, including the potential for CB (Staat & Segatore, 2005).
Education can allow patients to cope more effectively and the resulting awareness
may be able to provide some sense of control and encourage the family to connect
with an appropriate resource. As of 2009, there were no nationally known support
groups for CB, so the pediatric oncology nurse should strongly consider finding a
way to develop local groups (Evens & Eschiti, 2009).
Another intervention that is suggested to improve cognition during CB is
exercise. Evens & Eschiti (2009) stated that because exercise improves blood flow
and oxygenation to the brain, it might lead to improved cognitive functioning. They
also stated that acupuncture has recently been shown to dilate cerebral blood
vessels, which improves circulation as well as increases oxygenation to the brain.
When the non-pharmacological interventions are not sufficient, there are
some proposed pharmacological interventions to minimize the deficits of CB. Both
Ullrich & Embry (2012) and Staat & Segatore (2005) mentioned the use of
methylphenidate (Ritalin) as an option to help with inattention, organizational
skills, as well as forgetfulness. Both Evens & Eschiti (2009) and Staat & Segatore
(2005) discussed the use of erythropoietin and epoetin alfa. These drugs are used to
treat chemotherapy-induced anemia – they increase the oxygen carrying capacity of
blood, which in turn can lead to decreased ischemia and hypoxia in the brain,
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leading to cognitive improvement. Both sources also discuss the use of Gingko
Biloba. This herb is thought to have a neuroprotective, antioxidant, and membranestabilizing effect as well as possibly inhibiting the loss of cholinergic receptors,
which are known to have an impact on memory and cognition (Staat & Segatore,
2005).
Theoretical Framework
A theoretical framework that will guide the research is Erikson’s Theory of
Psychosocial Development. In this theory, Erikson divides the “life cycle” into eight
stages, and the focus of this project will be on the school-age stage of Industry versus
Inferiority. During this stage children will either begin to develop a sense of pride in their
accomplishments and abilities (industry) or will doubt their ability to be successful
(inferiority). According to Erikson (1950), when a child develops a sense of industry,
bringing “a productive situation to completion” is a goal that will gradually “supersede
the whims and wishes of play”. Simply put, the child will feel great satisfaction from
completing a task. Erikson also discusses the danger of this stage, feelings of inadequacy
or inferiority. Erikson (1950) states that if a child “despairs of his tools and skills or of his
status among his tool partners, her may be discouraged from identification with them”,
which may pull him back and result in isolation. In summary, if a child feels inadequate
and incompetent in what he does, he will start to pull back and considers himself
“doomed to mediocrity or inadequacy” (Erikson, 1950).
In the research, it is suggested that there are treatment related cognitive changes
that children experience both throughout treatment and long term. Cognitive changes
have become some of the most common and challenging problems associated with the
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CNS-directed treatment for certain forms of cancer (Moore et al., 2013). This can lead to
increasing gaps in their skills and knowledge compared to that of their classmates. This
gap can greatly impact their development of either industry or inferiority. Industry is
developed when a child can be confident and feel accomplished for tasks they are
completing, while inferiority can develop when a child feels they are unable to
accomplish tasks or be successful. With the gap in knowledge and skill that may be
present in these children who have undergone chemotherapy, there is a significantly
higher chance of them developing a sense of inferiority rather than the preferred sense of
industry. These children will notice they are unable to keep up and begin to doubt
themselves and their ability to be successful, further isolating them from their classmates.
Research Question
Based on what was reviewed and learned form the literature review, this study will
investigate the following questions:
1. How is “Chemo Brain” (CB) defined by the pediatric oncology nurses who
assess it?
2. According to the pediatric oncology nurses, what is the best evaluation of the
severity of CB?
3. How do pediatric oncology nurses describe their best practices to teach/support
patients and their families experiencing CB?
4. In conclusion, what are the best educational practices to teach about CB for
families under stress with a child with cancer?
Methods
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This is a qualitative/descriptive pilot study. In descriptive studies, there is no
manipulation of variables, and the focus is describing a phenomenon. The use of a
descriptive study design in this case is beneficial because for this is a pilot study this
researcher is soliciting personal experiences and knowledge. Pilot study results will
enable the researcher to determine if the instrument is valid for the proposed research
questions. This design can help to discover specific variables to manipulate and include
in future experimental research.
Subjects
Overall, the subjects of this study will be pediatric oncology registered nurses
(RNs) practicing in hospitals throughout the state. A majority of the subjects will be
members of the Bay Area/Northern California chapter of the Association of Pediatric
Hematology/Oncology Nurses (BAHPON) who attend the chapter educational event on
February 5, 2015. In addition to these nurses, other pediatric oncology RNs will be
recruited as subjects for the study through snowballing.
Sampling Procedure
Primarily, convenience sampling will be used. Convenience sampling is a nonprobability sampling technique where the research subjects are selected because of their
convenient accessibility and proximity to the researcher, such as access to members of
the BAHPON. With convenience sampling, the subjects are not representative of the
entire population. Snowball sampling will also be used to obtain subjects for the study.
Snowballing is also a non-probability sampling technique and may also be known as
chain referral sampling. Researchers use this technique when the subjects may be hard to
locate. Potential subjects are found through referral from existing subjects. In the case of
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this study, snowballing is used to reach out to other pediatric oncology RNs that may not
be members of BAHPON or may have not been in attendance at the meeting. The reason
for non-probability sampling for this study is that childhood cancer is very rare and very
few nurses select to work in this discipline. See Appendix A for a copy of the consent
letter.
Sample Size
For a small pilot study, the nursing research literature encourages approximately
13-50 subjects or elements for each variable identified. The goal sample size for this
study is 30 pediatric oncology RNs because the identified variables include assessment of
presence and severity, and best practices for education. Purposeful sampling techniques
will continue until the desired number of 30 is achieved or the date of March 1, 2015
dictates the completion of data collection.
Instruments
Research will be gathered through a survey given to pediatric oncology nurses.
This instrument begins by inquiring demographic information about the subjects. It then
asks both open-ended questions that explore RN’s perceptions and practices related to CB
and closed ended questions using a Likert scale. See Appendix B for a copy of the
instrument.
Reliability
For this pilot study, the researcher is concentrating on the development of a valid
instrument. When replicated, reliability will be tested using the techniques of
Chronbach’s Alpha.
Validity
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Two advanced practice RNs in pediatric oncology will provide instrument
construct and content validity. Construct validity is the extent to which inferences can be
made from the operationalizations in the study to the theoretical constructs on which the
operationalizations were based. Content validity refers to whether or not the items on the
instrument truly test what the study is looking at, and that the instrument is representative
of the research questions.
Step-by-Step Procedures
1. Receive IRB approval from the Dominican University of California Institutional
Review Board.
2. Contact the president of BAPHON and request for permission to attend the
February 5, 2015 meeting to give a short presentation of the study aims, methods,
and time frame.
3. If allowed, attend BAPOHN meeting and hand out copies of instrument.
4. Request contact information of BAPOHN members for sending out another round
of surveys to increase the amount of responses returned to primary investigator.
5. Contact and send out copies of the instrument to pediatric oncology nurses
reached through snowballing.
6. Continue to send out copies of the instrument to members of the BAPOHN and
other pediatric oncology nurses.
7. End collection of data on March 1, 2015.
8. Review all collected data.
9. Analyze the collected data.
10. Look for common themes in the open-ended responses.
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11. Discuss the significance of the results.

Statistical Analysis
Pending
Results
Pending
Discussion
Pending
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Appendix A
To Whom It May Concern:
My name is Jennifer Tapping and I am a senior nursing student at Dominican
University of California. I am currently working on my senior thesis research study.
I would like to invite you to participate in a research study that will be conducted
between December 2014 and March 2015, among pediatric oncology nurses. The
project is titled, “Nurse’s
Nurse’s Perceptions of Best Practices to Educate and Support
Pediatric Patients
nts and Their Families Experiencing “Chemo Brain:” A Pilot Study”
Background: With more advanced and more aggressive chemotherapy cancer treatment
leading to higher survival rates, complications with quality of life are becoming more
prominent, especially delayed cognitive processing, commonly known as “Chemo Brain”
Brain
(CB). At diagnosis and throughout treatment, patients and families are routinely educated
about the plan of care, but according to oncology nurses’ reports, too often details
regarding the possibility
ibility of cognitive declines or deficits are left out.
Cognitive changes are some of the most common as well as challenging complications
associated with central nervous system ((CNS) directed treatment, such as intrathecal
chemotherapy, for acute lympho
lymphoblastic leukemia (ALL) and brain tumors. The estimated
incidence of patients who experience deficits in cognitive processing related to their CNS
directed treatment is approximately 20% to 40% for children with ALL and 40% to 100%
for children with brain tumors
umors (Moore et al., 2013).
Purpose: The purpose of this study is three fold: 1) to define and discuss the etiology of
CB, 2) to discuss the best assessment and evaluation of severity of CB, and 3) to explore
pediatric oncology nurses’ reports of best pr
practice
actice implications for teaching and
supporting pediatric patients and their families experiencing CB.
Procedures: Data will be collected through a two
two-page
page survey instrument created by the
researcher that has construct and content validity provided by ttwo
wo advanced practice
registered nurses in pediatric oncology.
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Risks: This research study has no potential risks.
Benefits: By participating in this research, further exploration and understanding of the
best education and support practices related to CB in pediatric patients and their families
may be reached. This may benefit the future practical implications related to CB.
Costs: There are no costs involved in this research study other than the time given
completing the instrument.
Payments: There will be no payments for participation in this study.
Questions: If there are any questions about this study, the primary investigator, Jennifer
Tapping, may be contacted by email at jennifer.tapping@students.dominican.edu. In
addition, if there are concerns or any distress occurs as a result of this study, the research
advisor, Dr. Luanne Linnard-Palmer, who is a practicing pediatric oncology nurse, may
be contacted at (415)-257-1364
Consent: By completing the following instrument, consent is implied.
Thank you!
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Appendix B
Nurse’s Perceptions of Best Practices to Educate and Support Pediatric Patients and Their
Families Experiencing “Chemo Brain:” A Pilot Study
Date:__________________
Gender (circle one):

Male

Female

Age:___________________

Ethnicity:________________________________________________________________
Education Level:__________________________________
Level:__________________________________________________________
________________________
Years in Nursing:_________________________________________________________
Nursing:_______________________________________________________
Years in Pediatric Hematology/Oncology______________________________________
Hematology/Oncology_________________________________
Have you seen children with the neurological/central nervous system (CNS) toxicity
to
signs of “Chemo Brain” (CB)? (Circle one)
No

Yes

How do you define CB?____________________________________________________
CB?___________________________________________
________________________________________________________________________
__________________________________________
________________________________________________________________________
______________________________
How often do you see CB? (Circle one)
Never

Almost Never

Sometimes

Almost Always

Always

What primary symptom of CB have you seen?____________
seen?__________________________________
______________________
________________________________________________________________________
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How often do you include the possibility of CB in your treatment consent procedures?
(Circle one)
Never

Almost Never

Sometimes

Almost Always

Always

How do you describe/define CB to your patients and families?______________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
When does this discussion take place?_________________________________________
________________________________________________________________________
How does your facility asses the presence of CB in your patients?___________________
________________________________________________________________________
________________________________________________________________________
How does your facility assess the severity of CB in your patients?___________________
________________________________________________________________________
________________________________________________________________________
In your opinion, what are the best educational practices to teach families under stress
about CB?_______________________________________________________________
________________________________________________________________________
________________________________________________________________________
Is there anything else about CB you would like to share?__________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
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Thank you for your time!
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